Activity-based profiling of proteases

Annual Review of Biochemistry

Volumn 83, Issue , 2014, Pages 249-273

  Sanman, Laura E ^a   Bogyo, Matthew ^a,b,c  

^a Departments of Chemical and Systems Biology   (United States)

^b Microbiology and Immunology Department   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

activity based probes; affinity handle; fluorescent imaging; mass spectrometry; proteomics

Indexed keywords

ANTITRYPANOSOMAL AGENT; ASPARTIC ACID; ASPARTIC PROTEINASE; CALPAIN; CASPASE; CASPASE 7; CATHEPSIN K INHIBITOR; CATHEPSIN S; CYSTEINE; CYSTEINE PROTEINASE; DEUBIQUITINASE; ELECTROPHILE; FUNCTIONAL GROUP; KALLIKREIN 6; LEGUMAIN; METALLOPROTEINASE; MYELOBLASTIN; PAPAIN; PROTEASOME; PROTEINASE; SEPARASE; SERINE; SUMO PROTEIN; THREONINE; UROKINASE; BIOLOGICAL MARKER; PEPTIDE; PEPTIDE HYDROLASE;

BIOLOGY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CLOSTRIDIUM DIFFICILE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MOLECULAR PROBE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; TURNOVER TIME; ANIMAL; BIOCHEMISTRY; CHEMISTRY; DRUG DESIGN; MEDICINAL CHEMISTRY; PHYSIOLOGY; PROCEDURES; PROTEOMICS;

ANIMALS; BIOCHEMISTRY; BIOLOGICAL MARKERS; CASPASES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ESCHERICHIA COLI; HUMANS; PEPTIDE HYDROLASES; PEPTIDES; PROTEOMICS; SUBSTRATE SPECIFICITY;

EID: 84902181290     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-060713-035352     Document Type: Review

References (125)

1. Rawlings ND, Barrett AJ, Bateman A. 2012. MEROPS: the database of proteolytic enzymes, their substrates, and inhibitors. Nucleic Acids Res. 34:270-72
2. Turk B, Turk D, Turk V. 2012. Protease signalling: the cutting edge. EMBO J. 31:1630-43
3. Barrett AJ, Rawlings ND,Woessner JF. 1998. Handbook of Proteolytic Enzymes.Vol. 1. London: Academic
4. Turk B. 2006. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5:785-99
5. López-Ot́n C, Overall CM. 2002. Protease degradomics: A new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3:509-19
6. Edgington LE, Verdoes M, Bogyo M. 2011. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr. Opin. Chem. Biol. 15:798-805
7. Fonović M, Bogyo M. 2007. Activity based probes for proteases: Applications to biomarker discovery, molecular imaging and drug screening. Curr. Pharm. Des. 13:253-61
8. Deu E, VerdoesM, BogyoM. 2012. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat. Struct. Mol. Biol. 19:9-16
9. Turk V, Stoka V, Vasiljeva O, RenkoM, Sun T, et al. 2012. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824:68-88
10. Halfon S, Patel S, Vega F, Zurawski S, Zurawski G. 1998. Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett. 438:114-18
11. DixMM,SimonGM, Cravatt BF. 2008. Globalmapping of the topography andmagnitude of proteolytic events in apoptosis. Cell 134:679-91
12. Crawford ED,Wells JA. 2011. Caspase substrates and cellular remodeling. Annu. Rev. Biochem. 80:1055-86
13. Impens F, Colaert N, Helsens K, Ghesquière B, Timmerman E, et al. 2010. A quantitative proteomics design for systematic identification of protease cleavage events. Mol. Cell. Proteomics 9:2327-33
14. Kleifeld O, Doucet A, auf dem KellerU, Prudova A, SchillingO, et al. 2010. Isotopic labeling of terminal amines in complex samples identifies protein N-Termini and protease cleavage products. Nat. Biotechnol. 28:281-88
15. Yoshihara HA, Mahrus S, Wells JA. 2008. Tags for labeling protein N-Termini with subtiligase for proteomics. Bioorgan. Med. Chem. Lett. 18:6000-3
16. Timmer JC, EnokssonM,Wildfang E, ZhuW, Igarashi Y, et al. 2007. Profiling constitutive proteolytic events in vivo. Biochem. J. 407:41-48
17. Pop C, Salvesen GS. 2009. Human caspases: Activation, specificity, and regulation. J. Biol. Chem. 284:21777-81
18. Gross A, Yin X-M, Wang K, Wei MC, Jockel J, et al. 1999. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor R1/Fas death. J. Biol. Chem. 274:1156-63
19. Droga-Mazovec G, Bojič L, Petelin A, Ivanova S, Romih R, et al. 2008. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 283:19140-50
20. Crawford ED, Seaman JE, Agard N, Hsu GW, Julien O, et al. 2013. The DegraBase: A database of proteolysis in healthy and apoptotic human cells. Mol. Cell. Proteomics 12:813-24
21. Agard NJ, Mahrus S, Trinidad JC, Lynn A, Burlingame AL, Wells JA. 2012. Global kinetic analysis of proteolysis via quantitative targeted proteomics. Proc. Natl. Acad. Sci. USA 109:1913-18
22. Agard NJ, Maltby D, Wells JA. 2010. Inflammatory stimuli regulate caspase substrate profiles. Mol. Cell. Proteomics 9:880-93
23. Shimbo K, Hsu GW, Nguyen H, Mahrus S, Trinidad JC, et al. 2012. Quantitative profiling of caspasecleaved substrates reveals different drug-induced and cell-Type patterns in apoptosis. Proc. Natl. Acad. Sci. USA 109:12432-37
24. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, et al. 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Investig. 116:271-84
25. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-77
26. Koomen JM, Li D, Xiao L, Liu TC, Coombes KR, et al. 2005. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 4:972-81
27. Prudova A, auf dem Keller U, Butler GS, Overall CM. 2010. Multiplex N-Terminome analysis of MMP- 2 and MPP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol. Cell. Proteomics 9:894-911
28. Poreba M, Drag M. 2010. Current strategies for probing substrate specificity of proteases. Curr. Med. Chem. 17:3968-95
29. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. 2000. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. USA 97:7754-59
30. Otsuji T, Okuda-Ashitaka E, Kojima S, Akiyama H, Ito S, Ohmiya Y. 2004. Monitoring for dynamic biological processing by intramolecular bioluminescence resonance energy transfer system using secreted luciferase. Anal. Biochem. 329:230-37
31. Kim GB, Kim KH, Park YH, Ko S, Kim Y-P. 2013. Colorimetric assay of matrix metalloproteinase activity based on metal-induced self-Assembly of carboxy gold nanoparticles. Biosens. Bioelectron. 41:833-39
32. Tyas L, Brophy VA, Pope A, Rivett AJ, Tavare JM. 2000. Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep. 1:266-70
33. Fan H, Jiang X, Zhang T, Jin Q. 2012. Peptide-induced fluorescence quenching of conjugated polyelectrolyte for label-free, ultrasensitive and selective assay of protease activity. Biosens. Bioelectron. 34:221-26
34. Mizukami S, Takikawa R, Sugihara F, Hori Y, Tochio H, et al. 2008. Paramagnetic relaxation-based 19F MRI probe to detect protease activity. J. Am. Chem. Soc. 130:794-95
35. Kwong GA, vonMaltzahn G,Murugappan G, Abudayyeh O,Mo S, et al. 2013. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31:63-71
36. Puri AW, Broz P, Shen A, Monack DM, Bogyo M. 2012. Caspase-1 activity is required to bypass macrophage apoptosis upon Salmonella infection. Nat. Chem. Biol. 8:745-47
37. Cravatt BF, Wright AT, Kozarich JW. 2008. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77:383-414
38. Saville B. 1967. The concept of hard and soft acids and bases as applied tomulti-center chemical reactions. Angew. Chem. Int. Ed. Engl. 6:928-39
39. Powers JC, Asgian JL,EkiciOD,JamesKE. 2002. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102:4639-750
40. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, et al. 2005. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1:33-38
41. Thornberry NA, Peterson EP, Zhao JJ, Howard AD, Griffin PR, Chapman KT. 1994. Inactivation of interleukin-1βconverting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33:3934-40
42. Uhlmann F, Wernic D, Poupart MA, Koonin EV, Nasmyth K. 2000. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 103:375-86
43. Albrow VE, Ponder EL, FasciD, Békés M, Deu E, et al. 2011. Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. Chem. Biol. 18:722-32
44. Ekkebus R, van Kasteren SI, Kulathu Y, Scholten A, Berlin I, et al. 2013. On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J. Am. Chem. Soc. 135:2867-70
45. Yang Z, Fonović M, Verhelst SHL, Blum G, Bogyo M. 2009. Evaluation of alpha;,β-unsaturated ketonebased probes for papain-family cysteine proteases. Bioorgan. Med. Chem. 17:1071-78
46. Sexton KB, Kato D, Berger AB, Fonović M, Verhelst SHL, Bogyo M. 2007. Specificity of aza-peptide electrophile activity-based probes of caspases. Cell Death Differ. 14:727-32
47. Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt BF. 2004. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101:10000-5
48. Chau DM, Crump CJ, Villa JC, Scheinberg DA, Li YM. 2012. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J. Biol. Chem. 287:17288-96
49. Chan EWS, Chattopadhaya S, Panicker RC, Huang X, Yao SQ. 2004. Developing photoactive affinity probes for proteomic profiling: hydroxamate-based probes for metalloproteases. J. Am. Chem. Soc. 126:14435-46
50. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. 2002. Identification of signal peptide peptidase, a presenilin-Type aspartic protease. Science 296:2215-18
51. Falgueyret J-P, BlackWC,CromlishW,Desmarais S, Lamontagne S, et al. 2004. An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal. Biochem. 335:218-27
52. Abuelyaman AS, Hudig D, Woodard SL, Powers JC. 1994. Fluorescent derivatives of diphenyl [1-(npeptidylamino) alkyl]phosphonate esters: synthesis and use in the inhibition and cellular localization of serine proteases. Bioconjug. Chem. 5:400-5
53. Mahrus S, Craik CS. 2005. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem. Biol. 12:567-77
54. Serim S, Mayer SV, Verhelst SHL. 2013. Tuning activity-based probe selectivity for serine proteases by on-resin click construction of peptide diphenyl phosphonates. Org. Biomol. Chem. 11:5714-21
55. Verdoes M, Hillaert U, Florea BI, Sae-Heng M, Risseeuw MDP, et al. 2007. Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes. Bioorgan. Med. Chem. Lett. 17:6169-71
56. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M. 2000. Epoxide electrophiles as activitydependent cysteine protease profiling and discovery tools. Chem. Biol. 7:569-81
57. Jo H, Meinhardt N,Wu Y, Kulkarni S, Hu X, et al. 2012. Development of alpha;-helical calpain probes by mimicking a natural protein-protein interaction. J. Am. Chem. Soc. 134:17704-13
58. Patricelli MP,GiangDK, StampLM, Burbaum JJ. 2001. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1:1067-71
59. Rhoads ML, Fetterer RH. 1995. Regulated secretion of cathepsin L-like cysteine proteases by Haemonchus contortus. J. Parasitol. 81:505-12
60. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. 2000. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. Exp. Cell Res. 259:308-13
61. Dobrotǎ C, Fasci D, Hǎdade ND, Roiban GD, Pop C, et al. 2012. Glycine fluoromethylketones as SENP-specific activity based probes. ChemBioChem 13:80-84
62. Deu E, Leyva MJ, Albrow VE, Rice MJ, Ellman JA, Bogyo M. 2010. Functional studies of Plasmodium falciparum dipeptidyl aminopeptidase I using small molecule inhibitors and active site probes. Chem. Biol. 17:808-19
63. Wang G, Mahesh U, Chen GYJ, Yao SQ. 2003. Solid-phase synthesis of peptide vinyl sulfones as potential inhibitors and activity-based probes of cysteine proteases. Org. Lett. 5:737-40
64. Borodovsky A, OvaaH,MeesterWJ, Venanzi ES, BogyoMS, et al. 2005. Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. ChemBioChem 6:287-91
65. Bogyo M, McMaster J, Gaczynska M, Tortorella D, Goldberg A, Ploegh HL. 1997. Covalent modification of the active site threonine of proteasomal βsubunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA 94:6629-34
66. Arastu-Kapur S, Ponder EL, Fonović UP, Yeoh S, Yuan F, et al. 2008. Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat. Chem. Biol. 4:203-13
67. Vosyka O, Vinothkumar KR,Wolf EV, Brouwer AJ, Liskamp RMJ, Verhelst SHL. 2012. Activity-based probes for rhomboid proteases discovered in a mass spectrometry-based assay. Proc. Natl. Acad. Sci. USA 110:2472-77
68. Darzynkiewicz Z, Pozarowski P. 2007. All that glitters is not gold: All that FLICA binds is not caspase. A caution in data interpretation-And new opportunities. Cytometry A 71:536-37
69. Geurink PP, Prely LM, Van Der Marel GA, Bischoff R, Overkleeft HS. 2012. Photoaffinity labeling in activity-based protein profiling. Top. Curr. Chem. 324:85-113
70. Keow JY, Pond ED, Cisar JS, Cravatt BF, Crawford BD. 2012. Activity-based labeling of matrix metalloproteinases in living vertebrate embryos. PLoS ONE 7:e43434
71. Chun J, Yin YI, Yang G, Tarassishin L, Li Y, Hart C. 2004. Stereoselective synthesis of photoreactive peptidomimetic γ-secretase inhibitors. J. Org. Chem. 6:7344-47
72. Borodovsky A,OvaaH, Kolli N, Gan-Erdene T, Wilkinson KD, et al. 2002. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9:1149-59
73. Martin EJ, Blaney JM, Siani MA, Spellmeyer DC, Wong AK, Moos WH. 1995. Measuring diversity: experimental design of combinatorial libraries for drug discovery. J. Med. Chem. 38:1431-36
74. Kasperkiewicz P, Gajda AD, Drag M. 2012. Current and prospective applications of non-proteinogenic amino acids in profiling of proteases substrate specificity. Biol. Chem. 393:843-51
75. Vickers CJ, González-Páez GE, Wolan DW. 2013. Selective detection of caspase-3 versus caspase-7 using activity-based probes with key unnatural amino acids. Am. Chem. Soc. Chem. Biol. 8:1558-66
76. Heinis C, Rutherford T, Freund S, Winter G. 2009. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5:502-7
77. Baeriswyl V, Calzavarini S, Gerschheimer C, Diderich P, Angelillo-Scherrer A, Heinis C. 2013. Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy. J. Med. Chem. 56:3742-46
78. Pollaro L, Diderich P, Angelini A, Bellotto S, Wegner H, Heinis C. 2012. Measuring net protease activities in biological samples using selective peptidic inhibitors. Anal. Biochem. 427:18-20
79. Morell M, Nguyen Duc T, Willis AL, Syed S, Lee J, et al. 2013. Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. J. Am. Chem. Soc. 135:9139-48
80. Xiao J, Broz P, Puri AW, Deu E, Morell M, et al. 2013. A coupled protein and probe engineering approach for selective inhibition and activity-based probe labeling of the caspases. J. Am. Chem. Soc. 135:9130-38
81. Edgington LE, Verdoes M, Ortega A,Withana NP, Lee J, et al. 2013. Functional imaging of legumain in cancer using a new quenched activity-based probe. J. Am. Chem. Soc. 135:174-82
82. van Kampen JJ, Burgers PC, de Groot R, Gruters RA, Luider TM. 2011. Biomedical application of MALDI mass spectrometry for small-molecule analysis. Mass Spectrom. Rev. 30:101-20
83. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. 2007. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3:668-77
84. Kaplan HM, Hastings LP. 1947. The clinical use of fluorescein. Conn. State Med. J. 4:254-57
85. Witte MD,WalvoortMT, Li KY, KallemeijnWW, Donker-Koopman WE, et al. 2011. Activity-based profiling of retaining β-glucosidases: A comparative study. ChemBioChem 12:1263-69
86. Patricelli MP,GiangDK, StampLM, Burbaum JJ. 2001. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1:1067-71
87. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, et al. 2005. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2:357-62
88. Schmidinger H, Birner-Gruenberger R, Riesenhuber G, Saf R, Susani-Etzerodt H, Hermetter A. 2005. Novel fluorescent phosphonic acid esters for discrimination of lipases and esterases. ChemBioChem 6:1776-81
89. Flack JR, Krieger M, Goldstein JL, Brown MS. 1981. Preparation and spectral properties of lipophilic fluorescein derivatives: Application to plasma low-density lipoprotein. J. Am. Chem. Soc. 103:7396-98
90. Verdoes M, Oresic-Bender K, Segal E, van der Linden WA, Syed S, et al. 2013. An improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J. Am. Chem. Soc. 135:14726-30
91. Kolb HC, Finn MG, Sharpless KB. 2001. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl. 40:2004-21
92. BarglowKT, Cravatt BF. 2007. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4:822-27
93. BrummelKE. 2002. Thrombin functions during tissue factor-induced blood coagulation. Blood 100:148-52
94. Dickinson CD, Kelly CR, Ruf W. 1996. Identification of surface residuesmediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc. Natl. Acad. Sci. USA 93:14379-84
95. Sherratt AR, Blais DR, Ghasriani H, Pezacki JP, Goto NK. 2012. Activity-based protein profiling of the Escherichia coli GlpG rhomboid protein delineates the catalytic core. Biochemistry 51:7794-803
96. Berger AB, Witte MD, Denault J-B, Sadaghiani AM, Sexton KB, et al. 2006. Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol. Cell 23:509-21
97. Shen A, Lupardus PJ, Gersch MM, Puri AW, Albrow VE, et al. 2011. Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat. Struct. Mol. Biol. 18:364-72
98. Thomsen ND, Koerber JT, Wells JA. 2013. Structural snapshots reveal distinct mechanisms of procaspase-3 and -7 activation. Proc. Natl. Acad. Sci. USA 110:8477-82
99. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-63
100. Rupnik M, Pabst S, Rupnik M, von Eichel-Streiber C, Urlaub H, Söling HD. 2005. Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 151:199-208
101. Lupardus PJ, Shen A, BogyoM,Garcia KC. 2008. Small molecule-induced allosteric activation of Vibrio cholerae RTX cysteine protease domain. Science 322:265-68
102. Vinothkumar KR. 2011. Structure of rhomboid protease in a lipid environment. J. Mol. Biol. 407:232-47
103. Bachovchin DA, Brown SJ, RosenH, Cravatt BF. 2009. Substrate-free high-Throughput screening identifies selective inhibitors for uncharacterized enzymes. Nat. Biotechnol. 27:387-94
104. Lone AM, Bachovchin DA, Westwood D, Speers AE, Spicer TP, et al. 2012. A substrate-free activitybased protein profiling screen for the discovery of selective PREPL inhibitors. J. Am. Chem. Soc. 133:11665-74
105. Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, et al. 2010. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem. Commun. 46:7175-77
106. Kirby JM, AhernH, Roberts AK, Kumar V, Freeman Z, et al. 2009. Cwp84, a surface-Associated cysteine protease, plays a role in thematuration of the surface layer of Clostridium difficile. J. Biol. Chem. 284:34666-73
107. Barrett AJ, Kembhavi AA, Hanada K. 1981. E-64 [L-Trans-epoxysuccinyl- leucyl-Amido(4- guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. Acta Biol.Med.Ger. 40:1513-17
108. Baker N, de Koning HP, Máser P, Horn D. 2013. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 29:110-18
109. Stevens JR, Noyes HA, Dover GA, Gibson WC. 1999. The ancient and divergent origins of the human pathogenic trypanosomes, Trypanosoma brucei and T. cruzi. Parasitology 118:107-16
110. Yang PY, Wang M, Li L, Wu H, He CY, Yao SQ. 2012. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents. Chem. Eur. J. 18:6528-41
111. Saftig P,Hunziker E, Wehmeyer O, Jones S, Boyde A, et al. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice generation of mice. Proc. Natl. Acad. Sci. USA 95:13453-58
112. Deaton DN,Tavares FX. 2005. Design of cathepsin K inhibitors for osteoporosis. Curr. Top. Med. Chem. 5:1639-75
113. Desmarais S, BlackWC,Oballa R, Lamontagne S, Riendeau D, et al. 2008. Effect of cathepsinKinhibitor basicity on in vivo off-Target activities. Mol. Pharmacol. 73:147-56
114. Pejler G, Ronnberg E, Waern I, Wernersson S. 2010. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115:4981-90
115. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
116. Jessani N, Liu Y,HumphreyM,Cravatt BF. 2002. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA 99:10335-40
117. Cutter JL, Cohen NT, Wang J, Sloan AE, Cohen AR, et al. 2012. Topical application of activity-based probes for visualization of brain tumor tissue. PLoS ONE 7:e33060
118. Veilleux A, Black WC, Gauthier JY, Mellon C, Percival MD, et al. 2011. Probing cathepsin S activity in whole blood by the activity-based probe BIL-DMK: cellular distribution in human leukocyte populations and evidence of diurnal modulation. Anal. Biochem. 411:43-49
119. Jessani N, Liu Y,HumphreyM,Cravatt BF. 2002. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA 99:10335-40
120. Wiedl T, Arni S, Roschitzki B, Grossmann J, Collaud S, et al. 2011. Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J. Proteomics 74:1884-94
121. WiedlT,Collaud S,Hillinger S, Arni S, Burgess C, et al. 2012. KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics Proteomics 9:51-54
122. Patterson AW, Wood WJL, Hornsby M, Lesley S, Spraggon G, Ellman JA. 2006. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J. Med. Chem. 49:6298-307
123. Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, et al. 2012. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-Associated macrophages. Chem. Biol. 19:619-28
124. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, et al. 2000. Immunofluorometric assay of human kallikrein 6 and preliminary clinical applications. Clin. Biochem. 33:369-75
125. Oikonomopoulou K, Hansen KK, Baruch A, Hollenberg MD, Diamandis EP. 2008. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol. Chem. 389:747-56